Spero Therapeutics, Inc. Common Stock

SPRONASDAQ • USD
0.95 USD
↘ 0.05 (5.35%)AT CLOSE (03:59 PM EST)
0.94
↘ 0.01 (0.89%)
POST MARKET (AS OF 04:10 PM EST)
Post Market
AS OF 04:10 PM EST
0.94
↘ 0.01 (0.89%)
🟢Market: OPEN

Spero Therapeutics, Inc. Common Stock (SPRO) trades at $0.94 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, SPRO trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 16, 2026.

Open?$0.99
High?$0.99
Low?$0.90
Prev. Close?$1.00
Volume?594.5K
Avg. Volume?379.5K
VWAP?$0.94
Rel. Volume?1.57x
Bid / Ask
Bid?$0.81 × 100
Ask?$1.08 × 100
Spread?$0.27
Midpoint?$0.94
Valuation & Ratios
Market Cap?58.3M
Shares Out?58.2M
Float?42.1M
Float %?72.7%
P/E Ratio?N/A
P/B Ratio?74.60
EPS?-$0.51
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Employees
25
Market Cap
58.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2017-11-02
Address
675 MASSACHUSETTS AVENUE
CAMBRIDGE, MA 02139
Phone: 857-242-1600
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
69
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.09Distress
Confidence?47%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.87%Low
Short Interest?787.0K
Days to Cover?2.2
Free Float42.1M
Avg Daily Volume353.1K
Settlement Date2026-10-30
Financial Health
Current Ratio?1.92Adequate
Quick Ratio?1.92Adequate
Cash Ratio?1.89Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
74.60HIGH▾
P/S?
Peers
100
S&P
80
1.40CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
1.8CHEAP▾
EV/Sales?
S&P
97
-1.20CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-3,778.9%WEAK▾
ROA?
S&P
3
-26.8%WEAK▾
Cash Flow & Enterprise
FCF?$-40449000
Enterprise Value?$-49663423
Fundamentals ratios updated end of day